In this study, we treated patients with stage I-III breast cancer with evidence of DTCs following completion of neoadjuvant or adjuvant chemotherapy and HER2 targeted therapy (if indicated) with adjuvant ZOL for 24 months and evaluated serial quantitative changes in DTCs and CTCs. This evidence concerns the gene ERBB2 and breast carcinoma.